Streetbeat News

Stock Prices

GIL

Glenn J. Chamandy, former President and CEO of Gildan Activewear, criticized the company's board for actions he believes have undermined his record and damaged the company's reputation, leading to a significant loss in shareholder value. He disputes the board's claims and emphasizes the long-range plan presented in October 2023, which showed promising growth prospects for Gildan.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:19 pm

ICLR

ICON plc provided its fiscal year 2024 adjusted earnings per share (EPS) guidance of $14.50-$15.30, compared to the estimated $14.86. The company also forecasts revenue to be between $8.4 billion and $8.8 billion, versus the estimated $8.68 billion.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:17 pm

AXR

NBBK

VOXX

Insiders at AMREP Corporation, NB Bancorp, Inc., and VOXX International Corporation have made significant stock purchases, signaling potential confidence in their respective companies. AMREP's 10% owner bought shares despite a decline in quarterly sales. NB Bancorp's EVP acquired shares as the stock saw a slight gain over five days. VOXX International's Director made a substantial purchase following a settlement agreement with Seaguard.

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 1:17 pm

SUM

Summit Materials, Inc. (NYSE: SUM) has appointed Marshall Moore as EVP, Chief Operations Officer, effective January 4, 2024. Moore has a 35-year history in manufacturing and supply chain management, and previously held leadership roles at Synthomer and OMNOVA Solutions. His responsibilities at Summit will include enhancing operational excellence, integrating the acquisition of Argos USA, and driving value across all lines of business as part of the company's Elevate Strategy.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:17 pm

CREV

Carbon Revolution reported a significant increase in wheel production, with more than a tripling in Q4 and an 84% rise in the second half of the year compared to the first half.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:17 pm

MATX

TDCX

ZIM

Three industrial stocks, ZIM Integrated Shipping Services Ltd. (ZIM), Matson, Inc. (MATX), and TDCX Inc. (TDCX), are considered overbought based on their RSI values, which could signal a potential short-term pullback. ZIM recently partnered with Hoopo Systems for tracking devices, MATX reported strong Q3 results, and TDCX received a buyout proposal from its CEO.

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 1:15 pm

TMUS

T-Mobile US Inc. (NASDAQ:TMUS) stock is currently at $162.99, down 0.26% in the current session. Over the past month, TMUS stock increased by 1.59%, and over the past year, it rose by 9.54%. The company's P/E ratio of 25.37 is lower than the Wireless Telecommunication Services industry average of 37.18, which could suggest that TMUS is undervalued or expected to perform worse than its peers.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 1:15 pm

ABL

Abacus Life, Inc. (NASDAQ:ABL) has repurchased 206,050 shares at an average price of $9.26, spending approximately $1.9 million in the first 30 days of its $15 million stock repurchase program. The program, which began on December 12, 2023, has $13.1 million remaining and will expire on June 10, 2025. The company's CEO, Jay Jackson, expressed confidence in the business and its growth initiatives. Repurchases may continue through various methods and will be funded by cash on hand and future free cash flow.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:15 pm

OFIX

Orthofix Medical Inc. reported preliminary FY23 net sales of $746.3M, surpassing the consensus estimate of $741.52M. The company's year-over-year sales increased by 62% on a reported basis and 61.5% on a constant currency basis.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:13 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) has announced that an abstract related to its Phase 2 TFF TAC trial has been accepted for presentation at the ISHLT 2024 Meeting. The study involves a novel approach to delivering tacrolimus directly to the lungs to optimize immunosuppression for lung transplant patients, addressing the high unmet medical need in this area.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:13 pm